Cooper Companies
Market Cap
US$17.4b
Last Updated
2020/02/16 23:39 UTC
Data Sources
Company Financials +
Executive Summary
The Cooper Companies, Inc. operates as a medical device company worldwide.
Snowflake Analysis
Solid track record with adequate balance sheet.
Similar Companies
Share Price & News
How has Cooper Companies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: COO has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
1.5%
COO
2.2%
US Medical Equipment
1.5%
US Market
1 Year Return
26.6%
COO
22.1%
US Medical Equipment
20.1%
US Market
Return vs Industry: COO exceeded the US Medical Equipment industry which returned 22.1% over the past year.
Return vs Market: COO exceeded the US Market which returned 20.1% over the past year.
Shareholder returns
| COO | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 2.2% | 1.5% |
| 30 Day | -0.6% | 1.0% | 1.4% |
| 90 Day | 15.6% | 8.7% | 8.7% |
| 1 Year | 26.6%26.6% | 23.0%22.1% | 22.7%20.1% |
| 3 Year | 80.5%80.3% | 84.6%79.4% | 50.1%40.5% |
| 5 Year | 113.4%113.1% | 117.1%94.4% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is Cooper Companies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
The Cooper Companies, Inc. (NYSE:COO) Is Employing Capital Very Effectively2 weeks ago | Simply Wall St
A Look At The Intrinsic Value Of The Cooper Companies, Inc. (NYSE:COO)3 weeks ago | Simply Wall St
Is The Cooper Companies, Inc.'s (NYSE:COO) 13% ROE Better Than Average?Valuation
Is Cooper Companies undervalued compared to its fair value and its price relative to the market?
37.4x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: COO ($353.31) is trading above our estimate of fair value ($311.18)
Significantly Below Fair Value: COO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: COO is good value based on its PE Ratio (37.4x) compared to the Medical Equipment industry average (47.1x).
PE vs Market: COO is poor value based on its PE Ratio (37.4x) compared to the US market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: COO is poor value based on its PEG Ratio (3x)
Price to Book Ratio
PB vs Industry: COO is overvalued based on its PB Ratio (4.8x) compared to the US Medical Equipment industry average (4x).
Next Steps
Future Growth
How is Cooper Companies forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
12.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COO's forecast earnings growth (12.3% per year) is above the savings rate (1.7%).
Earnings vs Market: COO's earnings (12.3% per year) are forecast to grow slower than the US market (14.5% per year).
High Growth Earnings: COO's earnings are forecast to grow, but not significantly.
Revenue vs Market: COO's revenue (5.8% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: COO's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COO's Return on Equity is forecast to be low in 3 years time (15.4%).
Next Steps
Past Performance
How has Cooper Companies performed over the past 5 years?
10.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COO has high quality earnings.
Growing Profit Margin: COO's current net profit margins (17.6%) are higher than last year (5.5%).
Past Earnings Growth Analysis
Earnings Trend: COO's earnings have grown by 10.1% per year over the past 5 years.
Accelerating Growth: COO's earnings growth over the past year (233.6%) exceeds its 5-year average (10.1% per year).
Earnings vs Industry: COO earnings growth over the past year (233.6%) exceeded the Medical Equipment industry 7.1%.
Return on Equity
High ROE: COO's Return on Equity (12.9%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Cooper Companies's financial position?
Financial Position Analysis
Short Term Liabilities: COO's short term assets ($1.2B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: COO's short term assets ($1.2B) do not cover its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: COO's debt to equity ratio (50.3%) is considered high.
Reducing Debt: COO's debt to equity ratio has reduced from 53.4% to 50.3% over the past 5 years.
Debt Coverage: COO's debt is well covered by operating cash flow (39.1%).
Interest Coverage: COO's interest payments on its debt are well covered by EBIT (8.2x coverage).
Balance Sheet
Inventory Level: COO has a high level of physical assets or inventory.
Debt Coverage by Assets: COO's debt is not covered by short term assets (assets are 0.6x debt).
Next Steps
Dividend
What is Cooper Companies's current dividend yield, its reliability and sustainability?
0.016%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: COO's dividend (0.016%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.44%).
High Dividend: COO's dividend (0.016%) is low compared to the top 25% of dividend payers in the US market (3.69%).
Stability and Growth of Payments
Stable Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: COO is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of COO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Albert White (49yo)
1.8yrs
Tenure
US$7,724,745
Compensation
Mr. Albert G. White, III, has been President, Director and Chief Executive Officer of The Cooper Companies since May 1, 2018. Mr. White served as Chief Financial Officer of The Cooper Companies Inc. since ...
CEO Compensation Analysis
Compensation vs Market: Albert's total compensation ($USD7.72M) is about average for companies of similar size in the US market ($USD10.81M).
Compensation vs Earnings: Albert's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$7.72m | 0.082% $14.3m | |
| Senior VP | 1.8yrs | US$1.99m | 0.0060% $1.0m | |
| Executive VP & COO | 6.3yrs | US$3.58m | 0.070% $12.2m | |
| Executive VP & Chief Strategy Officer | 1.7yrs | US$2.51m | 0.00057% $99.0k | |
| President of Coopersurgical Inc | 1.8yrs | US$1.86m | 0.0080% $1.4m | |
| Senior VP of Finance & Tax and Chief Accounting Officer | 2.3yrs | US$1.21m | 0.0016% $276.2k | |
| Vice President of Investor Relations & Administration | 0yrs | no data | no data | |
| VP, General Counsel & Corporate Secretary | 6yrs | no data | 0.0034% $590.6k | |
| President of CooperVision Specialty EyeCare Division | 2yrs | no data | no data |
1.9yrs
Average Tenure
52yo
Average Age
Experienced Management: COO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$7.72m | 0.082% $14.3m | |
| Vice Chairman & Lead Director | 17.6yrs | US$472.28k | 0.0065% $1.1m | |
| Independent Chairman | 17.6yrs | US$594.40k | 0.038% $6.6m | |
| Non-Independent Director | 24.1yrs | US$375.48k | 0.29% $50.2m | |
| Independent Director | 28.1yrs | US$470.46k | 0.012% $2.1m | |
| Independent Director | 3.8yrs | US$447.46k | 0.0080% $1.4m | |
| Independent Director | 7.1yrs | US$452.46k | 0.0027% $472.5k | |
| Independent Director | 14.1yrs | US$467.96k | 0.038% $6.6m | |
| Independent Director | 3.8yrs | US$448.46k | 0.0074% $1.3m |
14.1yrs
Average Tenure
72yo
Average Age
Experienced Board: COO's board of directors are seasoned and experienced ( 14.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: COO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
The Cooper Companies, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: The Cooper Companies, Inc.
- Ticker: COO
- Exchange: NYSE
- Founded: 1980
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$17.371b
- Shares outstanding: 49.17m
- Website: https://www.coopercos.com
Number of Employees
Location
- The Cooper Companies, Inc.
- 6101 Bollinger Canyon Road
- Suite 500
- San Ramon
- California
- 94583
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| COO | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1983 |
| CP6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1983 |
| COO * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1983 |
| 0I3I | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1983 |
| C1OO34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 10 REPR 1 COM | BR | BRL | Jan 2020 |
Biography
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services focusing on women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive option, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, and distributors. The Cooper Companies, Inc. was founded in 1980 and is based in San Ramon, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 23:39 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/10/31 |
| Annual Earnings | 2019/10/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.